Provided by Tiger Trade Technology Pte. Ltd.

REVVITY INC

145.73
+5.543.95%
Post-market: 144.06-1.6734-1.15%19:06 EDT
Volume:3.40M
Turnover:495.09M
Market Cap:16.29B
PE:69.59
High:147.50
Open:140.88
Low:140.20
Close:140.19
52wk High:147.50
52wk Low:81.22
Shares:111.80M
Float Shares:102.00M
Volume Ratio:1.71
T/O Rate:3.34%
Dividend:0.28
Dividend Rate:0.19%
EPS(TTM):2.09
EPS(LYR):2.07
ROE:3.21%
ROA:2.37%
PB:2.25
PE(LYR):70.44

Loading ...

Revvity Is Maintained at Equal-Weight by Barclays

Dow Jones
·
May 08

Revvity Inc. Stock Climbs 7.4%, Outperforms Peers

Dow Jones
·
May 07

Revvity Inc. Stock Advances 6.7%, Outperforms Peers

Dow Jones
·
May 06

BUZZ-U.S. STOCKS ON THE MOVE-TransDigm, Rhythm Pharmaceuticals, Intel

Reuters
·
May 06

BUZZ-Revvity rises after first-quarter profit beat

Reuters
·
May 05

Stock Track | Revvity Soars 6.24% Intraday on Strong Q1 Earnings Beat and Strategic China Business Divestiture

Stock Track
·
May 05

Revvity Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05

Revvity Exec Says Seasonal Uptick Seen From Q1 to Q2; Margins Expected to Rise to About 29% in Q3 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says China Diagnostics Demand, Pricing Hit by Policy Headwinds - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Plans to Remain Prudent With Its Forward-Looking Assumptions - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co's Immuno-Diagnostics Business Declined in the Low Single Digits Organically in Q1 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Expects Q2 Organic Growth to Be in the Range of 2% to 3% - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Exepcts a Continuation, IF Not Acceleration, of Life Sciences Performance in Chine Through 2026 - Conf Call

THOMSON REUTERS
·
May 05

Revvity Exec Says Co Saw Positive Growth From Pharma and Academic Customer for the First Time Since Q2 2023 - Conf Call

THOMSON REUTERS
·
May 05

Revvity trims annual profit, sales forecast to exclude China immunodiagnostics unit

Reuters
·
May 05

GUIDANCE: (RVTY) Revvity Expects 2026 Adjusted EPS Range $5.20-$5.30, vs. FactSet Est of $5.39

MT Newswires Live
·
May 05

GUIDANCE: (RVTY) Revvity Expects 2026 Pro Forma Revenue Range $2.81B-$2.84B

MT Newswires Live
·
May 05

Revvity Q1 Adj. EPS $1.06 Beats $1.02 Estimate, Sales $711.118M Beat $705.134M Estimate.

Benzinga Earnings
·
May 05

Revvity Q1 GAAP EPS rises 5.7% to $0.37; revenue climbs 6.9% to $711 million

Reuters
·
May 05

BRIEF-Revvity Q1 Adjusted EPS USD 1.04 Vs. IBES Estimate USD 1.02

Reuters
·
May 05